EUCTR2012-002318-37-BE进行中（未招募）1 期
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes - The RELIEF Study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men or women aged = 18 years with a confirmed diagnosis of PV according to the revised World Health Organization criteria.
- •Subjects must currently be reporting symptoms on a stable dose of HU monotherapy and be eligible to continue HU on study after randomization. Before screening, the subject must have been receiving HU for at least 12 weeks and on the same dose for the last 4 weeks.
- •Subjects must have completed the modified MPN-SAF screening symptom form and have a screening total symptom score (TSS) of = 8 for the cytokine-related symptoms, or symptom cluster C (TSS-C): tiredness, itching, muscle aches, night sweats, and sweats while awake.
- •Subjects should meet at least one of the following criteria with respect to phlebotomy and splenomegaly:
- •- No more than 2 phlebotomies within the 6 months before screening OR
- •- No palpable splenomegaly
- •Subjects must have a hematocrit that can be controlled within 35% to 48% (inclusive) before randomization. (A phlebotomy may be performed during the screening phase to achieve this target range.)
- •Subjects must have recovered from all side effects associated with phlebotomy, and at least 1 week must have elapsed between the phlebotomy and the beginning of the baseline phase.
- •Subjects with Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Subjects with inadequate liver or renal function at screening as demonstrated by:
- •- Encephalopathy = Grade 2 as per Child-Pugh System
- •- Hepatocellular disease
- •- Total bilirubin > 2 × upper limit of normal (ULN), unless direct bilirubin is < 2 × ULN
- •- Alanine aminotransferase > 2.5 × ULN
- •- Modification of Diet in Renal Disease estimated glomerular filtration rate < 30 mL/min/1.73 m2 or on dialysis
- •Subjects with platelet count < 100 × 10^9/L or an absolute neutrophil count of < 1 × 10^9/L
- •Subjects with peripheral blood blast count of > 0% at screening.
研究者
相似试验
进行中（未招募）
1 期
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-GBIncyte Corporation110
进行中（未招募）
1 期
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-ESIncyte Corporation100
进行中（未招募）
1 期
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialMedDRA version: 14.1Level: HLGTClassification code 10018865Term: Haematopoietic neoplasms (excl leukaemias and lymphomas)System Organ Class: 10005329 - Blood and lymphatic system disordersPolycythemia VeraEUCTR2012-002318-37-ITINCYTE100
进行中（未招募）
不适用
Randomized Polycythemia Vera Symptom Study comparing the effectiveness and patient assessed effects of Ruxolitinib with Hydroxyurea in a Phase 3 trialPolycythemia VeraEUCTR2012-002318-37-IEIncyte Corporation100
已完成
3 期
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyPolycythemia VeraNCT01632904Incyte Corporation110